
|Articles|February 1, 2003
Progressive Systemic Sclerosis
Paris - Researchers at Jefferson Medical College are developing cutting edge techniques to attack the increased biosynthesis that appears to cause accumulation of collagen characteristic of scleroderma and particularly of a subset of the disease known as progressive systemic sclerosis (PSS), Jouni Uitto, M.D., Ph.D., chair, department of dermatology and cutaneous biology, said here at the World Congress of Dermatology.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
4
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
5














